Single-Use Bio Reactors Global Market Report 2024

A single-use bioreactor is a type of bioreactor that features a disposable bag instead of a traditional culture vessel. These bioreactors enable processors to utilize disposable technologies, including single-use bags, in steps that were traditionally reserved for stainless steel equipment.

The primary types of single-use bioreactors include stirred-tank SUBs (Single-Use Bioreactors), wave-induced SUBs, bubble-column SUBs, and other variations. Stirred-tank bioreactor designs, mimicking the functionality of traditional stirred-tank bioreactors, have gained increased market adoption. These bioreactors are employed in the production of various molecules such as vaccines, monoclonal antibodies, stem cells, and recombinant proteins, involving different cell types like mammalian cells, bacteria, and yeast. The applications of single-use bioreactors encompass research and development, process development, and bioproduction. End-users of these bioreactors include pharmaceutical and biopharmaceutical companies, contract research organizations (CROs), academic and research institutes, as well as contract manufacturing organizations (CMOs).

The single-use bioreactors market research report is one of a series of new reports that provides single-use bioreactors market statistics, including single-use bioreactors industry global market size, regional shares, competitors with a single-use bioreactors market share, detailed single-use bioreactors market segments, market trends and opportunities, and any further data you may need to thrive in the single-use bioreactors industry. This single-use bioreactors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The single-use bio reactors market size has grown rapidly in recent years. It will grow from $4.53 billion in 2023 to $5.39 billion in 2024 at a compound annual growth rate (CAGR) of 19.1%. The growth observed in the historical period can be attributed to several factors, including the growth of the biopharmaceutical industry, rapid development in bioprocessing, regulatory support for advancements, high adoption rates of precision medicine, and an increase in healthcare infrastructure.

The single-use bio reactors market size is expected to see exponential growth in the next few years. It will grow to $11.28 billion in 2028 at a compound annual growth rate (CAGR) of 20.3%. The anticipated growth in the forecast period can be attributed to various factors, including the increasing focus on personalized medicine and gene therapies, the growth of biopharmaceutical research and development activities, rising healthcare spending, and an enhanced emphasis on research and development in the pharmaceutical and biotechnology industries. Key trends expected in the forecast period include the integration of sensors and analytics in single-use bioreactors, the implementation of closed-system designs, customization and modularity of bioreactor systems, the incorporation of artificial intelligence (AI) and automation in bioprocessing, and the development of hybrid facilities combining single-use and traditional technologies.

The single-use bioreactor market is anticipated to witness growth due to an increasing demand for pharmaceutical products. Pharmaceutical products, designed to diagnose, prevent, treat, or cure diseases, have seen a surge in production, with the total pharmaceutical production in Europe reaching $351 billion (€300,000 million) in 2021, marking a 5% increase from $335.2 billion (€286,697 million) in 2020. Single-use bioreactors are integral in pharmaceutical manufacturing, particularly for biopharmaceuticals like antibodies, vaccines, and gene therapies, contributing to the market's expansion.

The growth of the single-use bioreactor market is further driven by the rising number of clinical trials. Clinical trials, crucial for assessing new medical treatments, interventions, or drugs, benefit from the advantages offered by single-use bioreactors, including rapid scalability, reduced cross-contamination risk, and shorter setup times. With an increase in registered studies reported by ClinicalTrials.gov, reaching 464,218 in 2023 compared to 399,496 in 2021, the market is poised to capitalize on the dynamic needs of clinical trials, with 31% in the U.S. and 53% in non-U.S. locations contributing to this growth.

Innovation in product offerings is a key trend in the single-use bioreactor market, with major companies introducing cutting-edge solutions. Thermo Fisher Scientific Inc., for example, launched single-use bioreactors with capacities of 3,000 liters and 5,000 liters in March 2021, surpassing conventional size limitations. These systems address the demand from contract development and manufacturing organizations (CDMOs) and pharmaceutical firms seeking diverse system sizes, offering increased scalability, improved turndown ratios, and enhanced mixing capabilities.

Technological advancements play a pivotal role, with companies developing state-of-the-art products such as X-platform bioreactors to stay competitive. Cytiva, a U.S.-based company, introduced X-platform bioreactors in April 2023, catering to single-use upstream bioprocessing needs. Equipped with the Figurate automation solution software, these bioreactors, available in sizes from 50 to 200 liters, aim to improve process efficiency by increasing production capacity, enhancing ergonomics, and streamlining supply chain operations.

In June 2023, Donaldson Company, Inc., a U.S.-based filtration company, acquired Univercells Technologies for $148 million. This acquisition enhances Donaldson's product portfolio, ensuring a comprehensive range of offerings in line with its life sciences strategy. Univercells Technologies, based in Belgium, specializes in single-use bioprocessing and bioreactor products.

Major companies operating in the single-use bio reactors market include CESCO Bioengineering Co Ltd., PBS Biotech Inc., Solida Biotechnology GmbH, ABEC Inc., Eppendorf AG, Sartorius Stedim Biotech Sa Ltd., Danaher Corporation Ltd., Thermo Fisher Scientific Inc., GE Healthcare, Merck Kgaa (Merck Millipore) Pvt Ltd., Distek Inc., Celltainer Biotech Bv Pvt.Ltd., Getinge AB, Pall Corporation, G&G Technologies Inc., SATAKE MultiMix Corporation, Bio-Age Equipment & Service Pvt.Ltd., Entegris Inc., Avantor Inc., Celartia, Cell Culture Company, Cytiva, Solaris Biotechnology srl., Cellexus International Ltd., Distek Inc., Infors AG, OmniBRx Biotechnologies, Xcellerex Inc., Applikon Biotechnology Inc., BBI-Biotech GmbH

North America was the largest region in the single use bioreactors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single-use bioreactors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the single-use bioreactors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The single-use bioreactors market consists of sales of stirrer single-use bioreactors and rocker single-use bioreactors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.